Medical Lovers Study Snaps

Goy Predicts Strategies for the Future of MCL Treatment Andre H. Goy, MD, predicts the future use of novel combinations for treatment of mantle cell lymphoma.

The Rationale for Dostarlimab Monotherapy In MSI-H and MSS Endometrial Cancer Ana Oaknin, MD, head of the Gynecologic Tumors Unit, Vall d’Hebron University Hospital, and principal investigator, Gynecological Malignancies Group, explains the rationale for analyzing anti–PD-1 monotherapy with dostarlimab in patients with microsatellite instability–hi...

Response to Checkpoint Inhibition in Urothelial Cancer May Be Affected by Autoimmune Events The development of an immune-related adverse event was associated with improved patient response in an FDA analysis of patients with advanced urothelial cancer treated with a PD-1/PD-L1 inhibitor.

Interpreting the Role of the Ramucirumab Plus Erlotinib Combination in EGFR+ NSCLC Marina C. Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy, discusses the results from the randomized phase III RELAY trial, in which the combination of ramucirumab plus erlotinib was compared to erlotinib plus placebo in patients...